Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ: TARS · Real-Time Price · USD
52.91
+0.91 (1.75%)
At close: Dec 20, 2024, 4:00 PM
52.66
-0.25 (-0.47%)
After-hours: Dec 20, 2024, 6:26 PM EST
Tarsus Pharmaceuticals Revenue
Tarsus Pharmaceuticals had revenue of $48.12M in the quarter ending September 30, 2024, with 2,471.78% growth. This brings the company's revenue in the last twelve months to $129.62M, up 801.96% year-over-year. In the year 2023, Tarsus Pharmaceuticals had annual revenue of $17.45M, down -32.42%.
Revenue (ttm)
$129.62M
Revenue Growth
+801.96%
P/S Ratio
14.82
Revenue / Employee
$531,234
Employees
244
Market Cap
2.02B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
PACS Group | 3.56B |
Alignment Healthcare | 2.47B |
Omnicell | 1.06B |
Supernus Pharmaceuticals | 651.97M |
TransMedics Group | 401.09M |
Mirum Pharmaceuticals | 307.03M |
Wave Life Sciences | 53.61M |
Agios Pharmaceuticals | 32.87M |
TARS News
- 6 days ago - Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's Top 2 Picks - Seeking Alpha
- 5 weeks ago - Tarsus Pharmaceuticals, Inc. (TARS) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors - GlobeNewsWire
- 6 weeks ago - Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024 - GlobeNewsWire
- 6 weeks ago - Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer - GlobeNewsWire
- 2 months ago - Tarsus Launches “Your Mitey Problem,” the First Direct-to-Consumer TV Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% - GlobeNewsWire
- 3 months ago - Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024 - GlobeNewsWire
- 3 months ago - Tarsus Pharmaceuticals: Unlocking Growth Potential With Eye Care Innovations - Seeking Alpha